Subbu Nambi
Stock Analyst at Guggenheim
(3.92)
# 593
Out of 5,131 analysts
71
Total ratings
49.18%
Success rate
12.82%
Average return
Main Sectors:
Stocks Rated by Subbu Nambi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Reiterates: Buy | $440 | $323.37 | +36.07% | 1 | Feb 10, 2026 | |
| TWST Twist Bioscience | Maintains: Buy | $77 → $79 | $49.11 | +60.86% | 3 | Jan 26, 2026 | |
| SOPH SOPHiA GENETICS | Maintains: Buy | $6 → $7 | $4.74 | +47.68% | 2 | Jan 26, 2026 | |
| PSNL Personalis | Maintains: Buy | $12 → $13 | $8.21 | +58.34% | 2 | Jan 26, 2026 | |
| ILMN Illumina | Maintains: Buy | $144 → $170 | $116.81 | +45.54% | 5 | Jan 26, 2026 | |
| GRAL GRAIL | Maintains: Buy | $100 → $130 | $97.50 | +33.33% | 3 | Jan 26, 2026 | |
| GH Guardant Health | Maintains: Buy | $115 → $135 | $104.85 | +28.76% | 8 | Jan 26, 2026 | |
| CSTL Castle Biosciences | Maintains: Buy | $43 → $47 | $33.18 | +41.65% | 3 | Jan 26, 2026 | |
| BRKR Bruker | Maintains: Buy | $53 → $58 | $36.51 | +58.86% | 5 | Jan 26, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Buy | $20 → $21 | $16.04 | +30.92% | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $10.94 | +9.69% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $35.80 | +39.66% | 5 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $270 | $206.23 | +30.92% | 3 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 → $275 | $212.58 | +29.36% | 3 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $103.24 | - | 4 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $170 | $90.15 | +88.57% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $96.03 | - | 1 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $95 | $51.95 | +82.87% | 4 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $36 | $20.62 | +74.59% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $8.37 | +19.47% | 1 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.49 | - | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.20 | +172.73% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.12 | - | 3 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $136.44 | - | 1 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.71 | - | 1 | Dec 14, 2023 |
Waters
Feb 10, 2026
Reiterates: Buy
Price Target: $440
Current: $323.37
Upside: +36.07%
Twist Bioscience
Jan 26, 2026
Maintains: Buy
Price Target: $77 → $79
Current: $49.11
Upside: +60.86%
SOPHiA GENETICS
Jan 26, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $4.74
Upside: +47.68%
Personalis
Jan 26, 2026
Maintains: Buy
Price Target: $12 → $13
Current: $8.21
Upside: +58.34%
Illumina
Jan 26, 2026
Maintains: Buy
Price Target: $144 → $170
Current: $116.81
Upside: +45.54%
GRAIL
Jan 26, 2026
Maintains: Buy
Price Target: $100 → $130
Current: $97.50
Upside: +33.33%
Guardant Health
Jan 26, 2026
Maintains: Buy
Price Target: $115 → $135
Current: $104.85
Upside: +28.76%
Castle Biosciences
Jan 26, 2026
Maintains: Buy
Price Target: $43 → $47
Current: $33.18
Upside: +41.65%
Bruker
Jan 26, 2026
Maintains: Buy
Price Target: $53 → $58
Current: $36.51
Upside: +58.86%
Adaptive Biotechnologies
Jan 26, 2026
Maintains: Buy
Price Target: $20 → $21
Current: $16.04
Upside: +30.92%
Jan 9, 2026
Maintains: Buy
Price Target: $8 → $12
Current: $10.94
Upside: +9.69%
Jan 5, 2026
Maintains: Buy
Price Target: $45 → $50
Current: $35.80
Upside: +39.66%
Jan 5, 2026
Maintains: Buy
Price Target: $230 → $270
Current: $206.23
Upside: +30.92%
Jan 5, 2026
Maintains: Buy
Price Target: $250 → $275
Current: $212.58
Upside: +29.36%
Nov 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $103.24
Upside: -
Oct 29, 2025
Maintains: Buy
Price Target: $115 → $170
Current: $90.15
Upside: +88.57%
Oct 16, 2025
Initiates: Neutral
Price Target: n/a
Current: $96.03
Upside: -
Sep 26, 2025
Maintains: Buy
Price Target: $80 → $95
Current: $51.95
Upside: +82.87%
Aug 13, 2025
Maintains: Buy
Price Target: $32 → $36
Current: $20.62
Upside: +74.59%
Apr 16, 2025
Reiterates: Buy
Price Target: $10
Current: $8.37
Upside: +19.47%
Apr 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.49
Upside: -
Jun 27, 2024
Initiates: Buy
Price Target: $6
Current: $2.20
Upside: +172.73%
Jun 26, 2024
Downgrades: Neutral
Price Target: n/a
Current: $18.12
Upside: -
Jun 18, 2024
Initiates: Neutral
Price Target: n/a
Current: $136.44
Upside: -
Dec 14, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.71
Upside: -